CMS has proposed extending new technology add-on payments for technologies that would otherwise be discontinued in fiscal year 2022.
Stryker's SpineJack, an implantable fracture reduction device, is one of 14 technologies included in the proposed rule, which would take effect Oct. 1.
SpineJack was recently granted CMS' New Technology Add-on Payment — or NTAP, which provides additional payment in the hospital inpatient setting.
CMS uses new technology add-on payments to accelerate the adoption of innovative devices meeting certain cost and clinical improvement criteria after FDA approval.
The agency pays the applicable Medicare Severity Diagnosis Related Group rate and up to an additional 65 percent of the cost of the technology.
"The new technology add-on payment is not budget neutral and is generally limited to the two- to three-year period following the date of the FDA approval or clearance for marketing," CMS said in an April 27 news release.
In addition to the new technology add-on payment, SpineJack also qualified for CMS' transitional pass-through payment, which provides outpatient facilities with incremental Medicare payment for the device for up to three years.